





A Platform for Drug-Drug Interaction Prediction





## **Our Team**



#### **Mai La** Data Scientist Data Engineer | MLOps



#### **Grace Lee**

Data Scientist Product Manager | UI



#### Radhika Mardikar

Data Scientist ML Engineer | UI



### 01

#### Impact

Opportunity Target Users

### 02

Product

Quick Demo

### 03

#### Approach

Details on data Scoping ML set up



#### Results

Evaluation Future Work Conclusion





# 01 Impact



=	

#### Drug - Drug interactions (DDI) can have severe effects

 52% of adverse drug effects are preventable<sup>1</sup> Account for 18.3% of all adverse drug effects<sup>2</sup>

22.4% of adults in the US use 5+ medications<sup>3</sup>

<sup>2</sup> Source: <u>Jiang et al., 2022</u>

### **Drug Interaction Testing is Expensive**



## **User Interviews**



#### **Pharmacist - Private**

• Manually find DDI



#### Supplement Co CEO

- Report for FDA
- Lots of testing



#### Org Chem PhD

- Chemical Formula
- Mechanism of Action



•

#### Pharmacist - CVS

Have built in database for searching



=		



## Optimize DDI testing and assist drug companies to bring new drugs to market

#### Input:

• SMILES (Simplified Molecular-Input Line-Entry System) Drug structure

COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C

• Mechanism of Action Pathway

This drug stops gastric acid secretion by selective inhibition of the H+/K+ ATPase enzyme system...

#### **Output**:

- Prediction Probability of Positive Interactions
- Breakdown of supplement vs
  medication
- Downloadable table with drug list and probabilities



## **O2 Product**





## **Product Feedback**



Dr. Han Dang, PharmD Pharmacy Manager



Mai Do, RPh. , MBA Pharmacy Manager, CVS



**Dr. Tuan La, PharmD** CEO, Global Express Pharmacy Impressive that AI could extract DDI for new drug development.

I was amazed by how fast this tool can help define possible interactions between a new drug with hundreds of available drugs at a very high level of accuracy. This definitely help drug discovery much faster and more efficient with a lower cost. Traditionally, the process of evaluating drug interactions might take months or years of experiments in vitro or in vivo. With DD.ai, it's less than 1 minute. Simply amazing!!!

Good start for interaction checker. It would bring greater values to the users by serving a high accurate AI model which focus on a certain drug family like antibiotics or cancer treatment drugs.



# **O3** Approach





### **Data Sources**

#### DrugBank (Features):

- Drug SMILES
- Action Pathway

#### Median Word Count / Token Length



#### NIH (Outcome):

• Drug Interactions





## **Key Considerations**



3	Ţ. Ţ.		
850+	SMILES	512	Drugbank
Interaction Types	Chemical structures	Tokens	data
Need to reduce	Non-traditional text encodings	Limitation for NLP	Limited to pairs of
scope		BERT encodings	drugs

## **Scope and Encodings**



#### Scope

850+ Class Prediction Unfeasible

**Binary Classification** 

#### **Text-based features**

#### **Morgan Similarity**

Encode SMILES chemical structures into vectors

#### Google Pegasus PubMed

Summarize large text blocks of drug information

#### **BioClinical BERT**

Encode above features for enhanced differentiability.



### Architecture







## Morgan Similarity



#### Key Takeaways:

- Encode SMILES with Morgan Similarity
- Create 300 clusters of encodings
- Take cosine similarity of new SMILES with 300 clusters to reduce dimensionality

## **Text Encodings**



#### **Google Pegasus PubMed**

Summarize large text blocks of drug

information



#### **BioClinical BERT**

Encode features using BERT model pre-trained on biomedical texts





# **04** Results



## **Model Registry**

Baselines

Improvement

Logistic Regression

F2: 70% AUPRC: 72%

Morgan Similarity Neural Net

F2: 73% AUPRC: 83%

Final

Morgan Similarity + BioClinicalBERT SMILES Only

F2: 83% AUPRC: 81%

XGBoost

F2: 70% AUPRC: 74%

BioClinicalBERT
 SMILES Only

F2: 81% AUPRC: 86%

Morgan Similarity + BioClinicalBERT SMILES & Pathway

F2: 83% AUPRC: 83%

### **Evaluation**

Morgan Similarity + BioClinicalBERT on SMILES & Pathway



### **Evaluation**



#### Further hypertuning in progress!

## **Future Developments**



#### **Product Focus**

Improve model predictions on specific drugs groups (i.e. antibiotics)



#### Modeling

Graph base GNN Additional features: target proteins



#### Encoding

Train BioBERT with drugs target & action pathway texts



#### Latency

Inference with GPU instances



## Accomplishments



#### New Drug Development

Inform potential DDI with drug formula

#### Scalability

Autoscaling with AKS



#### **NLP Model Serving**

Morgan Similarity + BioClinical BERT

#### **Interpretable Results**

Graphs and downloadable CSV





# Reimagine drug development by transforming drug-drug interaction detection



## Q&A Thank you!

dd-ai-predict.streamlit.app

## Acknowledgements

Professors:

- Joyce Shen
- Cornelia Ilin
- James Winegar

SME, Advisors:

- Roop Raich
- Tim Roth
- Dr. Han Dang, PharmD
- Mai Do, RPh. , MBA
- Dr. Tuan La, PharmD

## References

- 1. <u>Preventable ADE</u>
- 2. Percent of ADE
- 3. Adults using multiple medications
- 4. Drug Discovery Market Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023 – 2032
- 5. Drug Approvals
- 6. <u>BERTChem-DDI : Improved Drug-Drug Interaction Prediction from text using Chemical</u> <u>Structure Information.</u>
- 7. Drugbank: a knowledgebase for drugs, drug actions and drug targets
- 8. <u>SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules</u>
- 9. DrugBank database. Version 5.1.10. 2023
- 10. <u>Google/Pegasus-Pubmed</u>
- 11. Publicly Available Clinical BERT Embeddings



# Thanks

CREDITS: This presentation template was created by **Slidesgo**, including icons by **Flaticon**, and images by **Freepik**